Rasing Ingeborg, Ruigrok Ynte M, Greebe Paut, Velthuis Birgitta K, Witkamp Theo D, Wermer Marieke J H, Roos Yvo B, Vandertop W Peter, Rinkel Gabriel J E
From the Department of Neurology and Neurosurgery (I.R., Y.M.R., P.G., B.K.V., T.D.W., G.J.E.R.), Brain Centre Rudolf Magnus, University Medical Centre Utrecht; Leids Universitair Medisch Centrum (I.R., M.J.H.W.), Department of Neurology, Leiden; Neurosurgical Centre Amsterdam (Y.B.R., W.P.V.), Academic Medical Centre Amsterdam and VU University Medical Centre, Amsterdam, the Netherlands.
Neurology. 2015 Mar 3;84(9):912-7. doi: 10.1212/WNL.0000000000001310. Epub 2015 Jan 30.
The objective was to assess the risk of aneurysmal subarachnoid hemorrhage (aSAH) in the initial 15 years after negative aneurysm screening in persons with one first-degree relative with aSAH.
From a cohort of first-degree relatives of patients with aSAH who underwent screening between 1995 and 1997 (n = 626), we included those with a negative screening (n = 601). We retrieved all causes of death and sent a questionnaire to screenees who were still alive. If aSAH was reported, we reviewed all medical data. We assessed the incidence of aSAH in this cohort with survival analysis and calculated an incidence ratio by dividing the observed incidence with the age- and sex-adjusted incidence in the general population.
Of the 601 screenees, 3 had aSAH during 8,938 follow-up patient-years (mean 14.9 years). After 15 years, the cumulative incidence was 0.50% (95% confidence interval: 0.00%-1.06%) with an incidence rate of 33.6 per 100,000 person-years; the incidence rate ratio was 1.7 (95% confidence interval: 0.3-5.7).
In the first 15 years after a negative screening, the risk of aSAH in persons with one first-degree relative with aSAH is not nil, but in the range of that in the general population, or even higher. Whether this finding justifies serial aneurysm screening in this population requires further study.
评估在有一位患动脉瘤性蛛网膜下腔出血(aSAH)的一级亲属的人群中,动脉瘤筛查结果为阴性后的最初15年内发生aSAH的风险。
从1995年至1997年接受筛查的aSAH患者一级亲属队列(n = 626)中,我们纳入了筛查结果为阴性的患者(n = 601)。我们检索了所有死亡原因,并向仍在世的受检者发送了问卷。如果报告了aSAH,我们会查阅所有医疗数据。我们通过生存分析评估该队列中aSAH的发病率,并通过将观察到的发病率除以一般人群中年龄和性别调整后的发病率来计算发病率比。
在601名受检者中,3人在8938个随访患者年(平均14.9年)期间发生了aSAH。15年后,累积发病率为0.50%(95%置信区间:0.00% - 1.06%),发病率为每10万人年33.6例;发病率比为1.7(95%置信区间:0.3 - 5.7)。
在筛查结果为阴性后的最初15年里,有一位患aSAH的一级亲属的人群发生aSAH的风险并非为零,而是处于一般人群的范围内,甚至更高。这一发现是否足以证明对该人群进行系列动脉瘤筛查仍需进一步研究。